Publications by authors named "C Gomar"
Article Synopsis
- Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health issue linked to liver fat buildup and serious complications like cirrhosis and liver cancer.
- A study tested non-mitogenic FGF19 mRNA delivered in liver-targeted nanoparticles on mice with diet-induced obesity and MASH, finding it led to weight loss, improved insulin sensitivity, and reversal of MASH symptoms without worsening liver fibrosis.
- The treatment also altered liver bile acid levels, which may affect fat absorption and overall metabolism, suggesting promising prospects for mRNA-based therapies in treating MASH and related metabolic disorders.
Background: Lymphocytic choriomeningitis virus (LCMV) belongs to the Arenavirus family known for inducing strong cytotoxic T-cell responses in both mice and humans. LCMV has been engineered for the development of cancer immunotherapies, currently undergoing evaluation in phase I/II clinical trials. Initial findings have demonstrated safety and an exceptional ability to activate and expand tumor-specific T lymphocytes.
View Article and Find Full Text PDFPeritoneal carcinomatosis (PCa) represents a metastatic stage of a disease with unmet therapeutic options. Malignant cells from primary tumors (gastrointestinal or gynecologic malignancies) invade the peritoneal cavity and eventually seed onto peritoneal surfaces, with the omentum being the most common nest area. With a median survival of less than 6 months, PCa has a dismal prognosis that can be improved with treatments only available to a select few individuals with low tumor burden.
View Article and Find Full Text PDFBackground: Peritoneal carcinomatosis is an advanced stage of cancer in which the disease has spread to the peritoneal cavity. In order to restore antitumor immunity subverted by tumor cells in this location, we evaluated intraperitoneal administrations of modified vaccinia virus Ankara (MVA) engineered to express single-chain interleukin 12 (scIL-12) to increase antitumor immune responses.
Methods: MVA encoding scIL-12 (MVA.
Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure.
Mol Ther Nucleic Acids
September 2023
IL-12 is a potent cytokine for cancer immunotherapy. However, its systemic delivery as a recombinant protein has shown unacceptable toxicity in the clinic. Currently, the intratumoral injection of IL-12-encoding mRNA or DNA to avoid such side effects is being evaluated in clinical trials.
View Article and Find Full Text PDF